Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Osteogenesis-associated long non-coding RNA (lncRNA-OG)
- Target
- lncRNA-OG
- Molecular classification
- Long non-coding RNA (lncRNA), Non-coding RNA, Other (does not fit traditional categories like receptor, enzyme, transporter)
01
Overview
Osteogenesis-associated long non-coding RNA (lncRNA-OG) is a long intergenic non-protein coding RNA upregulated during the osteogenic differentiation of bone marrow-derived mesenchymal stem cells[1]. It acts epigenetically and through direct protein interactions (notably with hnRNPK) to regulate the expression of bone morphogenetic protein (BMP) family genes, particularly impacting the BMP/Smad1/5/8 signaling pathway. Its expression promotes differentiation of stem cells into osteoblasts—a major cellular component in bone formation—while knockdown inhibits this process. It operates mechanistically through modulation of promoter acetylation (H3K27ac), serving as a critical regulator of cellular fate in bone tissue. As such, it represents a novel therapeutic target for promoting bone regeneration, though no approved drugs yet directly target this lncRNA[1].
- Other names
- RP11-54A9.1lncRNA-OGosteogenesis-associated lncRNALINC02407long intergenic non-protein coding RNA 2407LNCOG
02
Mechanism of action
Gene silencing by LNA GapmeR antisense oligonucleotide inhibits lncRNA-OG and *delays* osteogenic differentiation Overexpression vectors or other gene augmentation strategies *promote* osteogenesis via upregulation of BMP family protein expression
03
Biological functions
Promotion of osteogenic differentiationRegulation of gene transcription (especially BMP family proteins)Epigenetic modulation (via H3K27 acetylation)Interaction with ribonucleoprotein complexes (notably hnRNPK)Stem cell fate determination
04
Disease associations
Bone development disordersOsteogenesis imperfecta (potentially relevant via deficient mechanism)Osteoporosis and other bone density diseasesPossibly abnormal bone formation in conditions like ossification of posterior longitudinal ligament, osteoarthritis, ankylosing spondylitis
05
Safety considerations
Broad specificity of non-coding RNA targeting can risk off-target effectsUnknown long-term effects in humans of manipulating lncRNA-OG expressionPotential for unwanted stimulation of bone formation in non-target tissuesNo safety data from clinical studies
06
Interacting drugs
No approved drugs currently target lncRNA-OG directly
2 more in the full profile.
07
Biomarkers
lncRNA-OG expression levels in BM-MSCs can serve as a potential biomarker for osteogenic potential or bone healing efficacyDownstream markers affected: RUNX2, ALP, osterix (OSX), osteocalcin (OCN)
Beyond the preview
Go deeper on Osteogenesis-associated long non-coding RNA (lncRNA-OG).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Osteogenesis-associated long non-coding RNA (lncRNA-OG).